hms-arthritis in systemic lupus erythematosus
TRANSCRIPT
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
1/30
Arthritis in Systemic Lupus
ErythematosusProf. Hermansyah
16/09/11 1
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
2/30
History
• 1948 – Malcolm Hargra es !isco ers thelupus erythematosus "LE# cell.
• 19$% – &he 'rst anti()*A anti+o!y isi!enti'e!.
16/09/11 2
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
3/30
Systemic Lupus Erythematosus
• ,n-ammatory autoimmune !iseaseof un no/n etiology
• Mor+i!ity – )isease associate! – 0orticosteroi! associate!
• 0orticosteroi! use as high as 89 1(2
• Mortality $(13 at 13 years – Early ( acti e !isease an! infections – Late ( atherosclerosis1. onana(*acach et al .5 2333 2. 6ro/it7 et al .5 A0 meeting 2333
"A+stract#
16/09/11 3
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
4/30
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
5/30
16/09/11 5
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
6/30
• Michael ac son has +een !iagnose!/ith lupus5 :o; *e/s is reporting <
=Systemic lupus erythematosus "SLEor lupus# is a chronic
16/09/11 6
http://www.foxnews.com/story/0,2933,300342,00.htmlhttp://www.foxnews.com/story/0,2933,300342,00.html
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
7/30
16/09/11 7
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
8/30
16/09/11 8
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
9/30
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
10/30
)amage /ithin SLESL,00>A0 )amage ,n!e; 1
Damage Index Domain N %
Musculoskeletal 121 22%Neuropsychiatric 110 20%Renal 79 1 %
!cular "# 1$%ardio&ascular '7 9%
(ulmonary $9 7%)kin ' #%(eripheral &ascular $' "%Dia*etes mellitus $0 "%
+astrointestinal 19 '%Malignancy 1' $%(remature gonadal ,ailure 12 2%1- .onana/Nacach et al - 2000
16/09/11 10
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
11/30
? er ie/ of 0linical &rial )esignProcess
• 0olla+orati e process +et/een@enela+s5 :)A an! 0onsultants
• 199$ Arthritis A! isory0ommittee – &/o e cacy per(patient en!points
• steroi! re!uction
• impro e! !isease acti ity• 1999 Arthritis A! isory
0ommittee – 0linical trial en!points !iscusse!
16/09/11 11
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
12/30
Primary E cacy En!point " espon!er#
Sustaine! pre!nisonere!uction < – Pre!nisone !ecrease! to ≤ %.$
mg>!ay• :or ≥ 2 consecuti e months
• ,nclu!ing last isit
16/09/11 12
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
13/30
1# e!uction in 0orticosteroi!eBuirements
• ,f SLE)A, /as sta+le or impro e!5an algorithm !ictate! steroi! taper
2# ,mpro ement or Sta+ili7ation of SLE• Case! upon impro ement or
sta+ili7ation in each of SLE)A,5SLAM5 D:SS an! Patient AS5/ithout clinical !eterioration
16/09/11 13
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
14/30
@enetic Associations
• HLAFs are loci on genes that co!e forcertain G chain on the MH0 comple;
• HLA() 2• HLA()• HLA()IC1 – ,n ol e! in me!iating
pro!uction of anti+o!ies to !s()*A
16/09/11 14
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
15/30
Cur!en of )isease
• Most patients ha e either recurrent-ares or continuously acti e !isease 1
• :lares remain common in esta+lishe!!isease 2
• Mor+i!ity also associate! /ithcorticosteroi! use
1. Carr et al .5 1999 J 2. Petri et al .5 1991J . onana(*acach5 et al .5 2333
16/09/11 15
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
16/30
Symptoms
• *on(speci'c< – :atigue – Keight loss
– Malaise generally feeling ill – :e er – Anore;ia "o er time# – Arthritis
• 93 of patients e;perience arthritic symptoms• Symmetrical• Appears in han!s5 /rists5 an! nees mainly
16/09/11 16
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
17/30
S in Manifestations• Malar or
Cutter-y ash• )iscoi! ash –
Stimulate! +y6 light• S in
manifestations
only appear in3(43 of lupuspatients.
16/09/11 17
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
18/30
enal "Di!ney#Manifestations
• $3(%3 of all lupuspatients e;perience renal!e elopments.
• Most )angerous< – @lomerulonephritis
/here at least $3 ofthe glomeruli ha ecellular proliferation
• @lomeruli – capillary+e!s in the i!neythat 'lter the +loo!.
• enal :ailure +ecause of@lomerulonephritis is thelea!ing cause of !eathamong lupus patients.
Normal
Glomerulonephritis16/09/11 18
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
19/30
?ther Manifestations
• 0ar!iac• 0entral *er ous System
• Hematological
16/09/11 19
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
20/30
Main Pathology
• &he plasma cells are pro!ucing anti+o!iesthat are speci'c for self proteins5 namely!s()*A
• ? eracti e C(cells• Suppresse! regulatory function in &(cells• Lac of &(cells
• Acti ation of the 0omplement system
16/09/11 20
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
21/30
? eracti e C(cells
• Estrogen is a stimulator of C(cell acti ity – Lupus is much more pre alent in females of
ages 1$(4$• Height of Estrogen pro!uction
• ,L(135 also a C(cell stimulator is in highconcentration in lupus patient serum. – High concentration lin e! to cell !amage
cause! +y in-ammation
16/09/11 21
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
22/30
&(cell Malfunctions
• :c region s/itch – NO – Lea!s to malfunction in signaling an!
!ecrease! ,L(2 pro!uction• ,ncrease! le els of 0a 2
– Lea!s to spontaneous apoptosis
16/09/11 22
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
23/30
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
24/30
Acti ation of 0omplement System
• 0omplement system is acti ate! +ythe +in!ing of anti+o!ies to foreign!e+ris. – ,n this case its o er acti ation
• C0s lac 0 1 receptor – )ecreasing the aQecti e remo al of
comple;es
16/09/11 24
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
25/30
,g@ Pathogen
• ,g@ is the most Rpathogenic+ecause it forms interme!iate si7e!comple;es that can get to the smallplaces an! +loc them.
16/09/11 25
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
26/30
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
27/30
&esting
• ES• 6rinalysis• 0omplement &est
– &ests le els of 0 5 045 0H$3 – Lo/ le els in!icates possi+le presence of
!isease• :A*A – :luorescent antinuclear anti+o!y• ?uchterlony &est – sho/s interactions
16/09/11 27
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
28/30
:A*A• EL,SA &est
– @enerally test for<• !s()*A
anti+o!ies
• Antihistoneanti+o!ies – Cin!s to )*A5
maTorconstituent of
chromatin• )eo;yri+onucleop
rotein ")*P#
16/09/11 28
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
29/30
?uchterlony &est• 6se! to !etermine
immunologicalspeci'city
• ules out a falsepositi e
• Sho/s the serum!oes or !oes notha e antinuclearanti+o!ies
16/09/11 29
-
8/9/2019 HMS-Arthritis in Systemic Lupus Erythematosus
30/30